SCHEMBL4676471

SCHEMBL4676471

O=C(Cc1ccc(S(=O)(=O)c2ccc(Cl)cc2)o1)C(=O)c1nn[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 6/20 0.35
TBXA2R P21731 1/20 0.33
POLB P06746 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.32
AKR1B1 P15121 1/20 0.32
NAMPT P43490 1/20 0.31
LMNA P02545 2/20 0.31
RPA1 P27694 1/20 0.31
XDH P47989 1/20 0.31
HSD17B2 P37059 1/20 0.30
NPC1 O15118 1/20 0.30
AGTR1 P30556 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
GPR55 Q9Y2T6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671298 0.90 CES1 (0.36) NAMPTHTTL3MBTL1
SCHEMBL4674810 0.89 CXCR3 (0.33) CXCR3POLBAKR1B1NAMPT
SCHEMBL4680308 0.82 L3MBTL1 (0.34) POLBALDH1A1CYP3A4MAPK1AKR1B1
SCHEMBL4679502 0.81 CXCR3 (0.35) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4671388 0.81 CXCR3 (0.36) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4672179 0.78 LOX (0.37) CXCR3ALDH1A1CYP3A4MAPK1
SCHEMBL4672144 0.77 CXCR3 (0.35) CXCR3TBXA2RPOLBALDH1A1CYP3A4
SCHEMBL4673305 0.77 CXCR3 (0.35) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4673905 0.77 CXCR3 (0.35) CXCR3TBXA2RPOLBALDH1A1CYP3A4
SCHEMBL4677045 0.77 CXCR3 (0.35) CXCR3TBXA2RPOLBALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CXCR3 1130/4885TBXA2R 2734/4885POLB 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.